v3.26.1
Segment Reporting - Segment net loss including segment expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 13, 2025
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Expenses              
Cost of sales - product   $ 3,762   $ 318   $ 6,532 $ 318
Cost of sales - intangible amortization   279   128   559 128
Research and development expenses   40,050   23,979      
Commercial expenses   11,899   8,364      
Medical affairs expenses   4,468   2,234      
General and administrative expenses   8,537   7,475      
Stock-based compensation expense   3,430   3,413      
Depreciation expense             10
Interest income   (1,108)   (822)   (2,405) (1,782)
Interest expense   360   212   743 404
Loss on debt extinguishment $ 1,800           1,826
Change in fair value of warrant liability       (20,320)   (9,323) (17,904)
Change in fair value of Notes   1,843   2,990   3,714 7,405
Other segment items   415   100      
Income tax expense   816       816  
Net loss   (34,673) $ (36,591) (25,934) $ (52,103) (71,264) (78,037)
Product revenue, net              
Revenue:              
Revenue   25,078   $ 2,137   43,749 2,137
Sale of COPIKTRA license and related assets              
Revenue:              
Revenue   $ 15,000       15,000  
Research, developing and commercialization drugs              
Expenses              
Cost of sales - product           6,532 318
Cost of sales - intangible amortization           559 128
Research and development expenses           77,422 52,532
Commercial expenses           21,775 12,417
Medical affairs expenses           7,576 4,459
General and administrative expenses           15,812 15,140
Stock-based compensation expense           5,476 5,084
Depreciation expense             10
Interest income           (2,405) (1,782)
Interest expense           743 404
Loss on debt extinguishment             1,826
Change in fair value of warrant liability           (9,323) (17,904)
Change in fair value of Notes           3,714 7,405
Other segment items           1,316 137
Income tax expense           816  
Net loss           $ (71,264) $ (78,037)
Segment reporting, other segment items           Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations. Other segment items primarily include severance expense and transactions losses and gains due to foreign currency fluctuations.
Research, developing and commercialization drugs | Product revenue, net              
Revenue:              
Revenue           $ 43,749 $ 2,137
Research, developing and commercialization drugs | Sale of COPIKTRA license and related assets              
Revenue:              
Revenue           $ 15,000